Post-Neoadjuvant Strategies in Breast Cancer (2nd Edition)

Dear Colleagues,

This Special Issue is the second edition of a previous issue on the topic of “Post-Neoadjuvant Strategies in Breast Cancer” (https://www.mdpi.com/journal/cancers/special_issues/Post_neoadjuvant_Cancers).

The post-neoadjuvant setting in early breast cancer is an attractive scenario for improving patient outcome by stratifying the adjuvant treatment according to the pathological response to the neoadjuvant systemic treatment. This strategy allows for studying new systemic therapies or new combinations of treatment modalities in high-risk patients who did not achieve pathologic complete response after primary treatment.

In this context, the findings after neoadjuvant therapy can be used as an in vivo sensitivity test, and further tailored treatment can improve the outcome in high-risk patients. Moreover, tailored de-escalation strategies of locoregional treatments could be another step towards reducing morbidity in patients with good response rates. To date, there is no clear evidence and there is no standard therapy routinely proposed for patients with residual disease after neoadjuvant chemotherapy, and few trials have addressed this setting. Therefore, the treatment of patients in the post-neoadjuvant setting remains a clinical challenge, with only a limited amount of data supporting the use of additional adjuvant chemotherapy.

The present Special Issue of Cancers focuses on recent advances and future perspectives in the various aspects of post-neoadjuvant strategies in breast cancer patients.

Prof. Dr. Edwin Bölke
Prof. Dr. Tanja Fehm
Dr. Stefanie Corradini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.